Madrigal Pharmaceuticals (MDGL) News Today

Sheaff Brock Investment Advisors LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,600 shares of the biopharmaceutical company's stock,

Cantor Fitzgerald reissued a "neutral" rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday.

Lord Abbett & CO. LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 97,103 shares of the biopharmaceutical com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 5% Higher

Susquehanna Fundamental Investments LLC acquired a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,186 shares of the b

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a

BNP Paribas Financial Markets reduced its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 50.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 11,374 shares of the biopharmaceutical company's stock after selling 11,395 share

StockNews.com upgraded Madrigal Pharmaceuticals to a "sell" rating in a report on Wednesday.

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 50.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 92,253 shares of the biopharmaceutical company's stock af

AMI Asset Management Corp raised its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 101.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,618 shares of the biopharmaceut

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 4,430,000 shares, a drop of 15.3% from the May 31st total of 5,230,000 shares. Based on an average trading volume of 468,300 shares, the short-interest ratio is currently 9.5 days.

Hennion & Walsh Asset Management Inc. boosted its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 20.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,318 shares of the

Rheos Capital Works Inc. bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 110,215 shares of the biopharm

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Up 3.8%

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) have received an average rating of "Moderate Buy" from the twelve analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assig

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 5.8%

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) VP Robert E. Waltermire sold 1,900 shares of the firm's stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $280.00, for a total value of $532,000.00. Following the sale, the vice president now owns 5,500 shares in the company, valued at $1,540,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Virtu Financial LLC purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,063 shares of the biopharmaceutical company's stock, valued at approx

Osterweis Capital Management Inc. increased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 96.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,147 shares of the b

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) VP Robert E. Waltermire sold 2,000 shares of the firm's stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $285.00, for a total value of $570,000.00. Following the completion of the transaction, the vice president now owns 5,500 shares in the company, valued at $1,567,500. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Frazier Life Sciences Management L.P. bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 69,406 shares of the bioph

Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 3.3%

Paulson & CO. Inc. increased its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 121.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,105,741 shares of the biopharmaceut

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 1.8%

Wolfe Research started coverage on shares of Madrigal Pharmaceuticals in a research note on Tuesday. They set an "outperform" rating and a $382.00 target price for the company.

Avoro Capital Advisors LLC boosted its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 21.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,888,888 shares of the biopharmaceutical company's stock after purchasing a

RTW Investments LP grew its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 163.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 815,191 shares of the biopharmaceutical company's stock after bu

StockNews.com upgraded shares of Madrigal Pharmaceuticals to a "sell" rating in a report on Wednesday.

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $244.35

Affinity Asset Advisors LLC lifted its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 17.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 100,000 shares of the biopharmaceutical company's stock after acquiring an

Rhenman & Partners Asset Management AB bought a new position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 22,500 shares of the biopharmaceutical comp

Norges Bank purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 145,589 shares of the biopharma

UBS Group AG grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 57.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 88,377 shares of the biopharmaceutical company's stock after purchasing an addition